

Clinical evaluation of Cernilton in benign prostatic hypertrophy

Hayashi J, Mitsui H, Yamakawa G, Suga A, Kai A, Shimabukuro T, Yanagi K, Fujisawa S, Takihara H, Kaneda Y, et al

Twenty patients with benign prostatic hypertrophy were treated with Cernilton, 6 tablets a day for an average of 13.2 weeks. Subjective effectiveness was observed in the improvement of sense of residual urine (92%), retardation (86%), night frequency (85%), strain on urination (56%), protraction (53%) and forceless urinary stream (53%). The overall subjective effectiveness was 80% of patients, and the overall objective effectiveness was 54% of patients. Night frequency, residual urine volume and tidal urine volume were improved significantly. The overall effectiveness was 80%. No side effects were observed.

PMID: 2421560, UI: 86183472

Hinyokika Kiyo 1986 Jan;32(1):135-41